Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
4
3
0
0
LUMOS PHARMA INC Share · US55028X1090 · LUMO · A2P12E (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LUMOS PHARMA INC
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float 65,46 %
Shares Float 5,66 M
Shares Outstanding 8,65 M
Company Profile for LUMOS PHARMA INC Share
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Company Data
Name LUMOS PHARMA INC
Company Lumos Pharma, Inc.
Symbol LUMO
Website
https://www.lumos-pharma.com
Primary Exchange 
NASDAQ
NASDAQ
WKN A2P12E
ISIN US55028X1090
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Richard J. Hawkins
Market Capitalization 38 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 4200 Marathon Boulevard, 78756 Austin
IPO Date 2011-11-11
Stock Splits
| Date | Split |
|---|---|
| 19.03.2020 | 1:9 |
ID Changes
| Date | From | To |
|---|---|---|
| 19.03.2020 | NLNK | LUMO |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | LUMO |
More Shares
Investors who hold LUMOS PHARMA INC also have the following shares in their portfolio:
